|
Overview
Since the appearance of CJD in humans, the spread of Transmissible Spongiform Encephalopathies through contaminated animal and human tissue and fluids has been of great concern to researchers producing therapeutics and diagnostics from these sources. The appearance of BSE in herds of cattle born after the introduction of the ruminant feed ban has raised new concerns and questions, as has the appearance of atypical cases of BSE and spread of Chronic Wasting Disease
(CWD) in North American deer herds. New data is advancing knowledge about the agent's ability to cross species barriers, transmission through blood transfusion, and options for detection and removal of the agent. Problems continue to exist in the areas of testing and reporting. This conference will present the newest data on TSEs in the context of their data on tses application to the pharmaceutical, food, biological, and device industry.
|
Scientific Advisors
|
Dr. David Asher, Lab Chief, Lab of Methods Development, FDA
Dr. Paul W. Brown
Dr. Larisa Cervenakova, The American National Red Cross
Dr. Kiki Hellman, The Hellman Group |
|
SCIENTIFIC SESSIONS
|
|
Advances in Understanding the Nature and Behavior of the Agent
|
|
De novo Generation of Mammalian Prions
In Vitro Generation of Infectivity by Protein Misfolding Cyclic Amplification (PMCA) and Use for Prion Detection in Blood
Early Events during TSE Infection
Transmission of Human TSE Diseases to Bank Voles
Studies on Pathogenesis, with Special Attention to Muscle Involvement
Pathologic PrP Deposition at the Cerebral Subcellular Level
|
|
|
Advances in Understanding
BSE/vCJD
|
|
Exposure to BSE Infectivity through Food in Great Britain throughout the BSE Epidemic
Variant Creutzfeldt-Jakob Disease and Blood Transfusion
Pathogenesis of vCJD in Non-Human Primates
Disease Phenotype and Transmission Properties of Bovine Amyloidotic Spongiform
Encephalopathy
Update on Chronic Wasting Disease
Sourcing Bovine Raw Materials for Pharmaceutical/Biological Use: Factors to Consider
|
|
| ADVANCES
IN Diagnostics
|
A Rapid Pre-Symptomatic Diagnostic Test for PrPsc in Tissue and Blood Using
Conformationally Sensitive PrP Peptide Ligands
Highly Sensitive TSE ELISA and its Application for Blood Screening
|
|
|
Advances In Prevention, Treatment, Inactivation and Removal
|
|
High-Throughput Screening for Inhibition of PrP-res Production in Cell
Culture and Testing
against Scrapie in Mice
A Case Study for the Inactivation of TSE Agents Using an Alkaline Treatment in
the Manufacturing Process of a Cell Culture Media Supplement
Novel Practical Decontamination Methods
Ultra-High Pressure Cooking of TSE-Spiked Meat Products
|
For more information please contact, fax, or e-mail submissions to:
Elizabeth Lamb, Conference Director, Cambridge Healthtech Institute
Fax: 207-493-4573 • E-mail: elamb@healthtech.com
For sponsorship information contact:
Carol Dinerstein at 781-972-5471 • Email: dinerstein@healthtech.com
|
